NasdaqGM:CHRSBiotechs
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses
Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic EPS loss of US$1.56. Over recent quarters, the company has seen revenue move from US$7.6 million in Q1 2025 to US$12.7 million in Q4 2025, with quarterly basic EPS losses in a tight band around US$0.38 to US$0.41. This keeps the focus squarely on how efficiently each extra dollar of sales is...